Abstract: A drug may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inhibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.

Abstract: A drug may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inihibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.

Abstract: A drag may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inhibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.

Abstract: A drug may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inhibits, antagonizes, or short circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.

Abstract: The present invention relates to aminoglycoside compounds having antibiotic activity. Moreover, the present invention relates to L-aminoglycoside compounds and diastereomers thereof which posses antibiotic activity and are not susceptible to development of resistant bacterial strains. The present invention also relates to methods of treatment and pharmaceutical compositions that utilize or comprise one or more of aminoglycoside compounds provided by the invention.

Abstract: Compounds used to treat cancer which inhibit carboxy terminal proteolysis of proteins having a carboxyl-terminal -CAAX motif (C=cysteine, A=aliphatic amino acid, and X=any amino acid). The compounds have the formula W--Y--CH.sub.2 --Q, where:1) W is a substituted or unsubstituted farnesyl group, a substituted or unsubstituted geranylgeranyl group, or a lipophilic alkyl, alkenyl, aryl or arylalkyl hydrocarbon group;2) Y is: ##STR1## wherein T.sub.1 is: --H, --CH.sub.3, --F, or --(CH.sub.2).sub.n --X.sub.1 ; in which n is an integer <20; and X.sub.1 is: --SH, --COOH, or --CONH.sub.2 ;T.sub.2 is: --N-benzxyloxycarbonyl (Boc), N--.phi.--, in which .phi. is an amino acid or a polypeptide reside; and ##STR2## wherein X.sub.2 is a peptide residue linked to carbon via the amino terminal nitrogen; and X.sub.3 is a peptide residue linked via an alpha carbon of the peptide; n is an integer <20, X.sub.4 is a halide and .beta. is an amino acid residue.

Abstract: This invention features compounds of the formula: W--Y--CH.sub.2 --Q wherein W is a farnesyl group, a geranylgeranyl group, a substituted farnesyl group or a substituted geranylgeranyl group or a lipophilic unsaturated hydrocarbon; Y is: --S--, --O--, --Se--, (I), (II), (III), (IV), (V) or --CH.sub.2 --; Q is (VI) wherein T.sub.1 is: H, F, or --(CH.sub.2).sub.n --X.sub.1 ; T.sub.2 is: --NHCOCH.sub.3, --NH(CH.sub.2).sub.n --X.sub.1, (VII) or a peptide of 20 or fewer amino acids; wherein X.sub.1 is: --SH, --COOH, or --CONH.sub.2 ; and n is an integer less than 20; T.sub.3 is: (VIII), (IX), (X), (XI), (XII), (XIII), (XIV), --CH.sub.2 --X.sub.2, (XV), (XVI), or --CF.sub.2 --X.sub.2 wherein X.sub.2 is a peptide of 20 or fewer amino acids linked to carbon via the amino terminal nitrogen of said peptide; X.sub.

Abstract: Disclosed are methods and kits for screening for compounds which bind to a target RNA, for isolating a target RNA from a sample, and for determining the presence and serum level of an aminoglycoside antibiotic in a subject. Also disclosed are kits for diagnosing the presence and identity of a bacterium or virus, and methods of increasing the potency of the binding interaction between an aminoglycoside antibiotic and a target RNA.

Abstract: The invention features a compound of the formulaW-Y-Q-Z or W-Y-ZwhereinW is a farnesyl group, a geranylgeranyl group, a substituted farnesyl group or a substituted geranylgeranyl group; ##STR1## wherein n=1, 2, 3, 4, 5, or 6; each of T.sub.1' . . . T.sub.n' and T.sub.1" . . . T.sub.n" is independently: Fl, Br, --NHCOCH.sub.3, --NH.sub.2, a peptide, an alkane group, an alkene group, an polyethyleneglycol group, a saturated fatty acid, an unsaturated fatty acid, a monosaccharide, or a disaccharide; andZ is --COOH or salts or esters thereof, --CONH.sub.2, --NO.sub.2, --PO.sub.3 or salts or esters thereof, --C N, or --SO.sub.3 or salts or esters thereof, provided that when W is farnesyl, Y is --S--, n=2, and either T.sub.2' or T.sub.2" is --NHCOCH.sub.3, then Z is not --COOH.The compounds of the invention are capable of interfering with enzymatic methylation of a peptide having the carboxyl-terminal motif --CAAX wherein C=cysteine, A=aliphatic amino acid, and X=any amino acid.